期刊
CLINICAL INFECTIOUS DISEASES
卷 55, 期 -, 页码 S3-S9出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cis393
关键词
-
资金
- Viral Hepatitis Action Coalition of the CDC Foundation
- Abbott Laboratories
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Genentech (Roche)
- Gilead Sciences
- GlaxoSmith-Kline
- Janssen Therapeutics
- Merck Sharp Dohme
- OraSure Technologies
- Vertex Pharmaceuticals
The impact of hepatitis C virus (HCV) infection on health and medical care in the United States is a major problem for infectious disease physicians. Although the incidence of HCV infection has declined markedly in the past 2 decades, chronic infection in 3 million or more residents now accounts for more disease and death in the United States than does human immunodeficiency virus (HIV)/AIDS. Current trends in the epidemiology of HCV infection include an apparent increase in young, often suburban heroin injection drug users who initiate use with oral prescription opioid drugs; infections in nonhospital healthcare (clinic) settings; and sexual transmission among HIV-infected persons. Infectious disease physicians will increasingly have the responsibility of diagnosing and treating HCV patients. An understanding of how these patients were infected is important for determining whom to screen and treat.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据